57th Annual Meeting

Dec 9-13, 2018

The Diplomat Beach Resort, Hollywood, Florida
More Annual Meeting Info


Jun 28, 2018

Honorific Award Nomination

Sep 5, 2018

Membership Application

Aug 10, 2018

Poster Abstract Submission

October 25, 2018

Early Registration Pricing

Digital Library Resources

Go to the Digital Library

Neuro News

A new era of rationally designed antipsychotics

Schizophrenia is a disorder that involves hallucinations, delusions, and cognitive impairment, and that affects nearly 1% of the global population1. The mainstays of therapy have been drugs that block the activity of the D2 dopamine receptor (D2R), a member of the large G-protein-coupled receptor (GPCR) superfamily of membrane proteins. Unfortunately, most of these antipsychotic drugs come with a plethora of debilitating side effects, many of which are due to off-target interactions with other GPCRs. In a paper in Nature, Wang et al.2 now report the crystal structure of D2R in complex with the antipsychotic drug risperidone. The structure reveals features that might be useful for the design or discovery of drugs that have greater selectivity for D2R than existing therapeutics, and consequently have fewer side effects.

The naturally occurring ligand for D2R is a neurotransmitter called dopamine, which mediates various physiological functions, including the control of coordinated movement, cognition and the reinforcing properties of drugs of abuse. There are five receptors for dopamine, which fall into two subgroups on the basis of their associated intracellular signalling pathways and their affinities for various drugs3: D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D3R and D4R). (Article - Nature News)

Read More


ACNP is a non-profit, professional society dedicated to advancing the scientific understanding of and facilitating communication about disorders of the brain and behavior in order to advance their prevention and treatment.